Vericel Earnings Call Transcripts
Fiscal Year 2026
-
The meeting confirmed a quorum, elected all board nominees, approved executive compensation, and ratified the auditor appointment. No shareholder proposals or questions were submitted.
-
Strong Q4 and full-year growth were driven by MACI and burn care, with a 30% sales force expansion and the Arthro launch fueling commercial momentum. Guidance for 2026 is balanced, with continued focus on operational excellence, pipeline progress, and ex-U.S. expansion targeted for 2027.
-
Advanced therapies for sports medicine and burn care drove strong 2024 results, with MACI and MACI Arthro fueling 20%+ growth and expanding market reach. New manufacturing capacity supports global expansion, while burn care and BARDA opportunities offer further upside.
-
Strong revenue and profit growth driven by MACI's market leadership and expansion, with new FDA approvals and a larger sales force supporting continued momentum. Burn care portfolio growth and new clinical studies position the company for further market expansion and operational excellence.
Fiscal Year 2025
-
Record Q4 and full-year revenue and profit growth were driven by strong MACI performance, margin expansion, and successful sales force expansion. 2026 guidance projects continued double-digit growth, with new clinical initiatives and international expansion on track.
-
Record Q3 results featured strong revenue, margin expansion, and robust cash generation. MACI growth is driven by increased surgeon training, Salesforce expansion, and new delivery methods, with international expansion planned for 2027. Burn care and NexoBrid show steady progress, while disciplined capital allocation supports long-term growth.
-
Record Q3 revenue and profit driven by strong MACI and burn care growth, with MACI Arthro adoption accelerating surgeon engagement and implant volumes. Guidance for 2025 and beyond remains robust, supported by ongoing investments and new clinical initiatives.
-
Advanced cell therapies and biologics are driving strong growth, with MACI Arthro expanding market reach and new sales force hires supporting future demand. Burn care products are building critical mass, and international and pipeline expansion are planned for the coming years.
-
Q2 saw 20% revenue growth, record gross margin, and adjusted EBITDA up 112% year-over-year. MACI and Burn Care segments both delivered strong results, with MACI Arthro driving new surgeon adoption and Epicel biopsies up nearly 40%. Full-year guidance for MACI is maintained, while Burn Care guidance is reset to reflect recent run rates.
-
Advanced therapies for sports medicine and burn care are driving strong revenue and margin growth, with MACI and Epicel leading their markets. MACI Arthro’s rapid adoption and expanded surgeon training are expected to accelerate growth, while capital investments position the company for increased cash generation and business development.
-
A unique portfolio in sports medicine and burn care, including MACI and NexoBrid, drives strong revenue and profit growth, with new product launches and market expansion fueling a 20%-23% growth outlook for 2024. Over 400 surgeons trained on MACI Arthro, and burn care adoption is accelerating.
-
Record Q1 revenue driven by MACI and NexoBrid growth, with Epicel rebounding in Q2. Full-year revenue and profitability guidance raised, supported by strong MACI Arthro adoption and upcoming Salesforce expansion.
-
Strong revenue and profit growth driven by leading cell therapies in sports medicine and burn care, with MACI and Epicel holding unique market positions and benefiting from regulatory and competitive barriers. Expansion into new indications, international markets, and continued innovation are expected to sustain high growth and profitability into 2025 and beyond.
Fiscal Year 2024
-
Delivered record 2024 results with 20% revenue growth, strong profitability, and cash flow. MACI and Burn Care franchises both grew over 20%, with MACI Arthro launch and new facility supporting future expansion. 2025 guidance projects continued high growth and margin expansion.
-
Q3 revenue grew 27% year-over-year to $57.9 million, with record results in both MACI and burn care segments. Margin expansion and cash flow were strong, and full-year guidance was raised for gross margin and Adjusted EBITDA. MACI Arthro and NexoBrid launches are expected to drive sustained growth.
-
The company reported strong financial growth, driven by its unique, FDA-approved cell therapy and burn care products. Recent FDA approvals for MACI Arthro and NexoBrid pediatric indication expand market opportunities, while profitability and margins continue to improve.
-
Advanced cell therapies and biologics drive strong growth, with record Q2 revenue, expanding indications for MACI and NexoBrid, and robust financials. New launches and pediatric expansion are set to further increase market reach and profitability.
-
Record Q2 revenue and margin expansion were driven by strong MACI and NexoBrid growth, with full-year guidance raised for profitability. MACI momentum is supported by expanding surgeon engagement and upcoming product launches, while burn care remains robust with new pediatric opportunities.
-
Strong Q1 results led to raised guidance, with MACI and Burn Care franchises showing early upside. MACI arthroscopic launch is set for Q3, supported by expanded training and sales resources. Margin expansion and cash generation enable continued investment and growth.